Cargando…

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

INTRODUCTION: We evaluated the three-year impact of adalimumab on patient-reported physical function and health-related quality-of-life (HRQOL) outcomes in patients with active ankylosing spondylitis (AS). METHODS: The Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS (ATLAS) is an ong...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Heijde, Désirée M, Revicki, Dennis A, Gooch, Katherine L, Wong, Robert L, Kupper, Hartmut, Harnam, Neesha, Thompson, Chris, Sieper, Joachim
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745808/ https://www.ncbi.nlm.nih.gov/pubmed/19686597 http://dx.doi.org/10.1186/ar2790

Ejemplares similares

Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab
por: van der Heijde, Désirée, et al.
Publicado: (2015)

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
por: Sieper, Joachim, et al.
Publicado: (2011)

Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years
por: van der Heijde, Désirée, et al.
Publicado: (2009)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
por: van der Heijde, D, et al.
Publicado: (2008)

Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis
por: Rudwaleit, Martin, et al.
Publicado: (2010)

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
por: van der Heijde, D, et al.
Publicado: (2008)

Predicting the outcome of ankylosing spondylitis therapy
por: Vastesaeger, Nathan, et al.
Publicado: (2011)

Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study
por: Revicki, Dennis A, et al.
Publicado: (2008)

Efficacy and safety of adalimumab in ankylosing spondylitis
por: Mounach, Aziza, et al.
Publicado: (2014)

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
por: Rudwaleit, Martin, et al.
Publicado: (2010)

Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
por: Ramiro, Sofia, et al.
Publicado: (2013)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Translation and validation of non-English versions of the Ankylosing Spondylitis Quality of Life (ASQOL) questionnaire
por: Doward, Lynda C, et al.
Publicado: (2007)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
por: van der Heijde, Désirée, et al.
Publicado: (2019)

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study
por: Webers, Casper, et al.
Publicado: (2018)

Adalimumab Therapy Restores the Gut Microbiota in Patients With Ankylosing Spondylitis
por: Chen, Zena, et al.
Publicado: (2021)

Adalimumab Mitigates Lumbar Radiculopathy in a Case of Ankylosing Spondylitis
por: Persaud, Trevor, et al.
Publicado: (2022)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
por: Braun, Juergen, et al.
Publicado: (2023)

Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients
por: Ding, Xiaoliang, et al.
Publicado: (2020)

The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
por: Baraliakos, Xenofon, et al.
Publicado: (2008)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy
por: Hennigan, Stephanie, et al.
Publicado: (2007)

Palmoplantar Pustulosis Induced by both Adalimumab and Golimumab for Treatment of Ankylosing Spondylitis
por: Seol, Jung Eun, et al.
Publicado: (2016)

Improvement of overlapping hidradenitis suppurativa and ankylosing spondylitis after the introduction of adalimumab
por: Bosnić, Dubravka, et al.
Publicado: (2016)

Allergic bronchopulmonary aspergillosis in a patient with ankylosing spondylitis treated with adalimumab
por: Suzuki, Yudai, et al.
Publicado: (2021)

Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab
por: Lee, Sang‐Hoon, et al.
Publicado: (2020)

Eosinophilia in a patient with ankylosing spondylitis treated with prolonged adalimumab only
por: He, Junhong, et al.
Publicado: (2022)

Reactive Arthritis Triggered by Adalimumab and Leflunomide in a Patient with Ankylosing Spondylitis
por: Liu, Ying, et al.
Publicado: (2022)

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
por: Baraliakos, Xenofon, et al.
Publicado: (2023)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
por: Braun, Jürgen, et al.
Publicado: (2018)

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials
por: Sieper, Joachim, et al.
Publicado: (2014)

Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China
por: Tu, Liudan, et al.
Publicado: (2020)

A Case of Adalimumab-Induced Psoriasiform Dermatitis in an Ankylosing Spondylitis Patient: Unusual Progression after Adalimumab Retreatment
por: Yoon, Ji Ha, et al.
Publicado: (2022)

The Long-Term Effects of Short-Period Adalimumab Biosimilar Usage in Ankylosing Spondylitis
por: Chopra, Arvind, et al.
Publicado: (2023)

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches
por: Braun, Juergen, et al.
Publicado: (2002)

Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study
por: Rudwaleit, M, et al.
Publicado: (2008)

Psychometric characteristics of the short form 36 health survey and functional assessment of chronic illness Therapy-Fatigue subscale for patients with ankylosing spondylitis
por: Revicki, Dennis A, et al.
Publicado: (2011)

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
por: Wagner, Carrie, et al.
Publicado: (2011)

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison
por: Maksymowych, Walter P., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6sk7cj8jvb4d9nttr1rnp3sfi7